Thermo Fisher Scientific has commercially introduced its fully integrated and automated mass spectrometry system, EXENTSolution.

The system is now available commercially in the UK, the Netherlands, Spain, Italy, Germany, France and Belgium.

EXENTSolution, which received in vitro diagnostic regulation (IVDR) certification, is intended to diagnose and evaluate patients with monoclonal gammopathies, including multiple myeloma.

Clinical laboratories can use the system for measuring, quantifying and tracking endogenous M-proteins and exogenous therapeutic monoclonal antibodies with improved analytical sensitivity and specificity in serum.

It features the EXENT-iP 500 automated sample preparation instrument, the EXENT-iX500 matrix-assisted laser desorption ionisation time of flight mass spectrometer and the EXENT-iQ intelligent and workflow software with data review.

To measure and quantify IgG, IgA, and IgM, the analyser is integrated with the EXENTimmunoglobulin isotypes immunoassay.

Developed utilising intellectual property from Mayo Clinic, the solution has key features, including dynamic monitoring of unique M-proteins and better visualisation.

Other features include simplified and less invasive serum testing, smart software with automated algorithm data processing and quantification with the Optilite analyser.

Thermo Fisher Protein Diagnostics chief scientific officer Dr Stephen Harding said: “The EXENT Solution represents a significant breakthrough in innovation for the detection and monitoring of monoclonal immunoglobulins.”

At the start of this year, the company concluded the acquisition of the Binding Site, adding protein diagnostics soluti
ons that included diagnosis and monitoring for monoclonal gammopathies to its speciality diagnostics portfolio.

Nectero Medical has secured fast-track designation from the US Food and Drug Administration (FDA) for its Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST) system.

The single-use endovascular system is intended for the treatment of patients with infrarenal abdominal aortic aneurysms (AAAs) with a maximum diameter of 3.5cm–5.0cm.

Nectero EAST consists of a stabiliser mixture containing pentagalloyl glucose (PGG) and a dual-balloon delivery catheter.

The system administers PGG locally to the aneurysmal wall, where it attaches to elastin and collagen, strengthening the aortic vessel wall and lowering further degradation risk.

Designed to finish within an hour, the procedure does not need any specialised tools and leaves no permanent implant.

Furthermore, it does not prevent future interventions. The company is commencing a randomised, controlled Phase II/III trial (stAAAble) to assess the safety and effectiveness of Nectero EAST.

Nectero Medical president and CEO Jack Springer said: “This designation reinforces Nectero Medical’s belief that the Nectero EAST System has the potential to address a large segment of patients who suffer from a serious progressive disease with no proven treatment options.

“Available therapies are reserved primarily for patients who fall into the highest-risk category. “We are proud to be advancing a treatment that has the potential to impact so many lives and are extremely pleased that the FDA acknowledged this through our designation.”

More than one million people in the US are anticipated to live with AAA and approximately 60,000 undergo treatment for this condition each year. The complications of AAA result in roughly 10,000 deaths annually in the country.

Medtronic plc, a global leader in healthcare technology, has received CE Mark approval for its Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS). It is the first Medtronic SCS device to offer a closed-loop feature that senses each person’s unique biological signals and adjusts stimulation moment to moment, as needed, to keep therapy in harmony with the motions of daily life. †

Spinal cord stimulators deliver mild electrical impulses to the spinal cord, which can disrupt pain signals before they reach the brain. As patients go about their daily lives, certain movements may result in uncomfortable stimulation. This in turn may lead some patients to turn down their device’s stimulation output, resulting in a suboptimal therapy experience. By contrast, Inceptiv is able to sense the body’s neural response to stimulation 50 times per second, every second of every day. When neural response increases, such as when the patient coughs, sneezes, or bends, Inceptiv automatically decreases stimulation. As neural response decreases, stimulation returns to the pre-set optimal level. This is done seamlessly to provide consistent therapy while patients perform a full range of daily activities.

“Today, fixed-output spinal cord stimulation does not account for patient movements, which can alter the distance between the spinal cord and implanted epidural leads,” said Dirk Rasche, M.D., from the Department of Neurosurgery, University Hospital of Schleswig-Holstein in Lübeck, Germany. “This can compromise the patient´s experience and therapeutic effectiveness. The Inceptiv closed-loop feature will allow for a more consistent and optimal delivery of therapy, and reduced need for manual programming adjustments by the patient. Together with the compatibility of multiple types of waveform options, inclusive of DTM™ SCS, and industry-leading MRI access, I believe this latest generation of rechargeable neurostimulator represents a significant leap forward in SCS therapy and a milestone of modern neuromodulation.”

The Inceptiv device utilizes a closed-loop capability with ECAPs (Evoked Compound Action Potentials), resulting from decades of Medtronic research and development to unlock the ability to listen and respond to signals along the spinal cord. ECAPs are a direct measure of how much neural tissue is activated in the spinal cord in response to electrical stimuli, providing real-time information that enables the system to respond to patient movements. In a clinical study, 9 out of 10 patients preferred the optional closed-loop setting compared to fixed-output stimulation.1

“Medtronic pioneered SCS for pain management more than 50 years ago, and we continue to deliver new innovations that personalize care and improve pain relief for patients,” said Ash Sharan, M.D., chief medical officer, Neuromodulation, which is part of the Neuroscience Portfolio at Medtronic. “This approval marks the beginning of a new era of pain relief, using sensing technology to listen to the unique biological signals of each patient.”

The Inceptiv neurostimulator is the only SCS system in Europe offering both full-body 1.5T and 3T MRI access.‡ Most people with SCS will need an MRI within five years of receiving their device.2 Inceptiv is also the thinnest SCS device in the world at just 6mm, and it offers the proven benefits of Medtronic’s proprietary DTM™ spinal cord stimulation. The system’s battery can be recharged from empty to full in approximately one hour.

GE HealthCare announced the launch of Vscan Air SL – a handheld, wireless ultrasound imaging system designed for rapid cardiac and vascular assessments at the point of care to help clinicians accelerate diagnoses and treatment decisions. The latest addition to the Vscan product suite, Vscan Air SL features GE HealthCare’s proprietary SignalMax and XDclear technology that provide high levels of penetration, resolution, and sensitivity in imaging performance with an industry-leading single crystal transducer technology.

With cardiovascular disease the most prevalent disease worldwide[i] often presenting in emergency situations, prompt diagnosis and treatment can be vital. The portable, wireless Vscan Air SL is designed to enable clinicians to efficiently collect and view crystal clear cardiac and vascular images at the point of care. By streamlining these workflows and avoiding overloading traditional radiology resources, clinicians can expedite care decisions to help patients receive treatment plans right away when time is of the essence.

“Having ever more powerful handheld ultrasound is a game changer for patient care,” said Guy Lloyd, M.D., FRCP, consultant cardiologist at Barts Heart Center, University College London Hospitals and clinical director for Cardiovascular Diagnostics and Investigations. “Whether on the ward or in general practice, being able to provide high-quality imaging at the point of care means rapid diagnosis and rapid treatment.”

With Vscan Air SL, clinicians have a pocket-sized, portable tool that allows for clear, whole-body scanning and secure viewing of images. In addition, through Vscan Air + Digital Tools, clinicians have access to subscriptions that can connect them to a suite of easy-to-use solutions designed to improve workflow with secure collaboration, image, and device management features.

“Vscan Air SL enables clinicians to make quick cardiac assessments and adds to our broad portfolio of ultrasound technologies to help further inform clinical decision making at the point of care,” said Dietmar Seifriedsberger, Global General Manager, Point of Care and Handheld Ultrasound at GE HealthCare. “This newest innovation demonstrates our commitment to providing integrated solutions resulting in better standard of care delivery — and ultimately helping clinicians improve patient outcomes.”

GE HealthCare pioneered the first color pocket-sized ultrasound, Vscan, in 2010 and has since continued to revolutionize the way clinicians treat patients. In 2021, GE HealthCare introduced one of the smallest and most lightweight handheld ultrasound devices with the Vscan Air CL. To date, there are more than 50,000 systems from the Vscan product suite in the pockets of clinicians, impacting the care of more than an estimated 100 million patients worldwide.[ii] Vscan Air CL and SL continue the company’s commitment to innovation and transforming the clinical exam by making it easier to acquire high quality ultrasound images.

GE HealthCare is showcasing Vscan Air SL at the European Society of Cardiology (ESC) 2023 annual meeting in Amsterdam, Netherlands Friday, August 25 – Monday, August 28 in booth #H500. The booth features the theme “Know. Now.” with information and resources to raise awareness of the importance of early detection of cardiovascular disease for better patient outcomes.

Vscan Air SL is currently commercially available in key countries throughout Europe and Asia as well as Australia and New Zealand. In the United States, Vscan Air SL is 510(k) cleared by the U.S. Food and Drug Administration and will become commercially available this quarter.

Israel-based medical device company BioProtect has secured approval from the US Food and Drug Administration (FDA) for its new biodegradable balloon.

Named BioProtect Balloon ImplantSystem, the new generation spacer has been developed to offer consistent, reproducible and optimal protection to the rectum during radiation therapy for prostate cancer.

It is an implantable balloon that offers a specific enclosed distance to reduce radiation exposure to the rectum while undergoing therapy.

Designed to provide reproducible separation between the prostate and rectum, the spacer can be viewed under all imaging modalities, such as ultrasound, magnetic resonance imaging and computerised tomography.

Utilising a blunted tip insertion device, the biodegradable spacer can be deployed through a rapid and minimally invasive procedure.

BioProtect CEO Itay Barnea said: “We believe that our balloon has the potential to revolutionise rectal protection from toxicity during prostate cancer radiation therapy.

“Not only does it provide better protection to healthy organs, it also supports dose escalation and hypofractionation, which are leading trends in prostate cancer radiation therapy.”

As per the American Cancer Society, prostate cancer is the second-most prevalent cancer among men in the US, with 288,300 newly diagnosed cases this year.

The company has appointed Ken Knudson as general manager and chief commercial officer to advance its penetration into the US market.

The BioProtect Balloon spacer is already commercialised in Europe and is supported by the Consensus Business Group of Vincent Tchenguiz, Peregrine Ventures, KB Investment, Almeda Ventures and Triventures.

Abbott announced late-breaking data from the first-of-its-kind ILUMIEN IV OPTIMAL PCI (ILUMIEN IV) clinical study, a randomized global imaging trial. The study found that during percutaneous coronary interventions (PCI), guidance with optical coherence tomography (OCT) compared to angiography helps physicians achieve improved stent expansion for a greater minimal stent area (MSA). According to the study, OCT guidance during PCI is associated with a lower risk of stent thrombosis (ST), a potentially fatal complication of PCI procedures.

The results of ILUMIEN IV were presented as a late-breaking clinical trial at the European Society of Cardiology (ESC) Congress 2023 in Amsterdam, Netherlands (August 25-28, 2023) and simultaneously published in The New England Journal of Medicine.

Currently, coronary angiography (use of X-ray to assess blood vessels) is the standard of care for guidance when physicians implant stents to treat patients with coronary heart disease. OCT imaging provides doctors with additional high-definition images that improve visualization of vessel structure, giving actionable data that translate into patient benefits, according to the new ILUMIEN IV findings. These findings have the potential to shift physicians’ approaches to treating patients with complex coronary disease.

“The ILUMIEN IV results should have a major impact on clinical practice,” said Gregg W. Stone, M.D., the ILUMIEN IV study chairman, director of academic affairs for the Mount Sinai Health System and professor of medicine (cardiology) and population health science and policy at the Icahn Mount Sinai. “The demonstration that stent thrombosis is reduced by approximately two-thirds with OCT is especially important as most patients who develop stent thrombosis die or have a heart attack. OCT guidance also reduced angiographic complications and led to better stent implantation.”

ILUMIEN IV included patients with medication-treated diabetes and or complex-artery disease exclusively. The study evaluated OCT-guided stent implantation compared to stenting using angiography alone in 2,487 patients from 18 countries at 80 sites across numerous regions of the world, from India to the U.S. and Japan to Europe.

The study showed:

Improved stent expansion. ILUMIEN IV data showed OCT guidance resulted in a statistically significant 7% increase in MSA compared to angiography guidance alone. A larger MSA has shown correlation with a reduction in future adverse events in previous studies. [1],[2]
Reduced risk of future blockages. OCT guidance was associated with a 64% reduction in ST rates, resulting in a statistically significant difference compared to angiographic guidance.

Additional safety benefits. OCT guided PCIs vs. angiography was associated with a 39% reduction in cardiac death and 24% reduction in target vessel myocardial infarction, respectively.

While the study met its primary imaging endpoint of improving MSA, it did not achieve superiority in reducing the primary clinical endpoint, target vessel failure (TVF), a composite of cardiac death, myocardial infarction (MI) and target vessel revascularization (TVR) at two years. Despite the numeric reductions in both cardiac death and target vessel MI when OCT was used, the lack of differentiation in TVR may have been impacted by the COVID-19 pandemic, regional variations in routine practice, and access to healthcare.

“The ILUMIEN IV data demonstrate the impact that OCT guidance can have when treating patients with complex coronary disease,” said Nick West M.D., chief medical officer and divisional vice president of global medical affairs at Abbott’s vascular business. “In these cases, angiography alone simply cannot match the precision afforded by OCT to determine a treatment plan.”

Ultreon™ Software, the latest OCT offering from Abbott, is the only intracoronary imaging solution on the market powered by artificial intelligence, guiding stents to be placed with precision. This leading technology provides enhanced views of coronary anatomy and blockages to help support physicians’ decision-making in real time.

Hormone replacement therapy (HRT) has become an increasingly popular treatment for individuals seeking to transition or alleviate symptoms of menopause. However, accessing HRT can be challenging for those who live in rural areas or have limited access to healthcare providers. Fortunately, the rise of telehealth has made it easier for individuals to access HRT from the comfort of their own homes.

Telehealth HRT provides a safe and convenient alternative to traditional in-person appointments. Patients can connect with healthcare providers online, eliminating the need for travel and reducing wait times.

As telehealth continues to reshape healthcare, HRT via telehealth is becoming an increasingly popular option for individuals seeking hormone therapy. With its convenience, accessibility, and inclusivity, telehealth HRT is transforming the way individuals access and receive hormone therapy.

Understanding Telehealth and Hormone Replacement Therapy

The Concept of Telehealth

Telehealth is a healthcare delivery method that uses telecommunication technologies to provide medical care and services remotely. It allows patients to access healthcare services from the comfort of their homes, eliminating the need to visit a physical clinic or hospital. Telehealth is a convenient and cost-effective way to receive medical care, especially for individuals who live in remote areas, have mobility issues, or have busy schedules.

Telehealth services include primary care and specialist consultations, medication review visits, and support groups. One of the most exciting possibilities of telehealth is hormone replacement therapy (HRT). HRT is a medical treatment that involves replacing hormones that the body no longer produces in sufficient quantities. It is commonly used to treat menopause symptoms, such as hot flashes, mood swings, and vaginal dryness.

Overview of Hormone Replacement Therapy

Hormones are chemical messengers that regulate various bodily functions, including growth, metabolism, and reproduction. As individuals age, their hormone levels decline, which can lead to a range of health problems. HRT involves replacing hormones, such as estrogen and progesterone, to alleviate symptoms of hormone deficiency.

HRT can be administered in various forms, including pills, patches, gels, creams, and injections. The type of HRT prescribed depends on the individual’s symptoms, medical history, and preferences. Telehealth HRT clinics such as Amazing Meds offer a convenient and accessible way to receive hormone replacement therapy from the comfort of one’s home.

Telehealth HRT services are especially beneficial for individuals who live in remote areas or have limited access to healthcare services. They can also be useful for individuals who have mobility issues or have busy schedules that make it difficult to attend in-person appointments. Telehealth HRT services offer a convenient and cost-effective way to receive hormone replacement therapy, improving the quality of life for many individuals.

The Role of Telehealth in Hormone Care

Telehealth is revolutionizing the healthcare industry by providing convenient and accessible care to patients. Hormone replacement therapy (HRT) is one area of healthcare that has benefited greatly from telehealth services. Here are some ways in which telehealth is changing the landscape of hormone care:

Telehealth Visits

Telehealth visits allow patients to receive care from the comfort of their own homes. Patients can schedule appointments with their healthcare provider and have a video consultation without having to travel to a physical clinic. This is particularly beneficial for patients who live in remote areas or have mobility issues. Telehealth visits also reduce the risk of exposure to infectious diseases, making it a safer option for patients.

Electronic Communications

Telehealth also allows for electronic communications between patients and healthcare providers. Patients can communicate with their provider through secure messaging, email, or phone calls. This allows patients to ask questions, receive test results, and get prescriptions refilled without having to make an appointment. Electronic communications also allow healthcare providers to monitor patients’ progress and adjust treatment plans as needed.

Care from Home

Telehealth services allow patients to receive hormone care from the comfort of their own homes. Patients can order their medication online and have it delivered directly to their doorstep. This eliminates the need for patients to go to a physical pharmacy, which can be difficult for those who have mobility issues or live in remote areas. Patients can also monitor their hormone levels at home using at-home testing kits and send the results to their healthcare provider for review.

Benefits of HRT Via Telehealth

Hormone replacement therapy (HRT) is a medical treatment that can help alleviate symptoms of hormonal imbalance, such as hot flashes, mood swings, and fatigue. Traditionally, HRT requires in-person visits to a healthcare provider, which can be inconvenient for some patients. However, with the rise of telehealth, patients can now receive HRT from the comfort of their own homes.

Accessibility and Convenience

One of the main benefits of HRT via telehealth is increased accessibility and convenience. Patients no longer need to take time off work or travel long distances to attend appointments with their healthcare provider. Instead, they can schedule virtual visits from their home or office, saving time and money. This is especially beneficial for patients who live in rural or remote areas, where access to healthcare may be limited.

Overcoming Geographic Barriers

Telehealth also allows patients to overcome geographic barriers. Patients who live far away from their healthcare provider can now receive HRT without having to travel long distances. This is particularly important for patients who may have mobility issues or who live in areas with limited public transportation. Telehealth also allows patients to receive care from providers who are not located in their immediate area, giving them access to a wider range of healthcare options.

Personalized Treatment Plan

Another benefit of HRT via telehealth is the ability to receive personalized treatment plans. Telehealth providers can use digital tools to collect information about a patient’s medical history, symptoms, and lifestyle, which can be used to create a personalized treatment plan. This can improve the effectiveness of HRT and reduce the risk of side effects. Additionally, telehealth providers can monitor patients remotely, allowing them to make adjustments to the treatment plan as needed.

Role of Healthcare Providers in Online Hormone Care

When it comes to online hormone care, healthcare providers play a crucial role in ensuring that patients receive proper treatment and care. There are two main types of healthcare providers involved in online hormone care: primary care providers and specialist practitioners.

Primary Care Providers

Primary care providers are often the first point of contact for patients seeking hormone therapy. They are responsible for assessing the patient’s overall health and determining whether hormone therapy is an appropriate treatment option. Primary care providers may also be responsible for prescribing hormone therapy and monitoring the patient’s progress.

In the context of online hormone care, primary care providers must be able to provide comprehensive care and support to patients remotely. This may involve conducting virtual consultations and follow-up appointments, as well as providing patients with resources and information to help them manage their hormone therapy.

Specialist Practitioners

Specialist practitioners, such as endocrinologists, gynecologists, and urologists, play a critical role in providing specialized care to patients undergoing hormone therapy. They have extensive knowledge and expertise in hormonal disorders and are trained to manage complex cases.

In the context of online hormone care, specialist practitioners may be consulted by primary care providers to provide specialized care and support to patients. They may also conduct virtual consultations and follow-up appointments to monitor the patient’s progress and adjust their treatment plan as needed.

Overall, healthcare providers are essential to the success of online hormone care. They must be knowledgeable, skilled, and compassionate in their approach to providing care and support to patients undergoing hormone therapy. By working together, primary care providers and specialist practitioners can ensure that patients receive the best possible care and achieve optimal health outcomes.

IHH Healthcare Bhd  through its wholly-owned subsidiary Gleneagles Development Private Limited, has today entered into an agreement to buy out the entire remaining stake held by Dr Ravindranath Kancherla and his affiliates in Ravindranath GE Medical Associates Private Limited (“RGE”) for a total purchase consideration of approximately INR 7,400 million (equivalent to approximately RM 415 million).

Dr Ravindranath is the founder of RGE, which owns the chain of Gleneagles Global Hospitals, a leading tertiary and quaternary healthcare chain in India, including specialising in comprehensive multi-organ transplant services. Gleneagles Global Hospitals operates 6 multi-super-specialty hospitals across Hyderabad, Chennai, Bangalore, and Mumbai, with a capacity of approximately 1,500 beds and stateof the-art, world-class facilities.

The transaction is expected to complete by the fourth quarter of 2023. With this transaction, IHH will strengthen its leading position as a tertiary and quaternary care platform, including multi-organ transplants, in India and across its key markets.

The Royal Flying Doctor Service (RFDS), Australia’s rural and remote health services provider, has launched a new nationwide Aeromedical Electronic Health Record (EHR) powered by Oracle Autonomous Database, running on Oracle Cloud Infrastructure (OCI), to streamline clinical information collection and analysis leading to faster and better decision-making by medical staff. By moving to the cloud, RFDS has reduced administrative workloads and lowered its data management costs by approximately 20 percent.

One of the largest aeromedical organisations in the world, RFDS provides primary healthcare and 24-hour emergency services to those living in rural and remote Australia. The organisation performs 1,000 patient interactions a day and prior to moving to cloud relied heavily on paper-based processes and disparate, standalone record management solutions. As a result, significant administration efforts, to keep patient records updated, are time consuming to compile, frequently duplicated, and challenging to manage. RFDS welcomed a unified, cost-effective data management system with strong cybersecurity and data compliance posture to manage organisation-wide patient records.

“We are committed to bringing first-class healthcare and emergency services to people in the hard to reach areas of Australia. By using Oracle Autonomous Database, we’ve been able to digitise and consolidate our medical records systems. As a result, we have improved the accuracy, accessibility, and security of information for better continuity of care,” said Ryan Klose, chief information officer, RFDS. “In this journey we are undertaking with Oracle, our destination is a fast, frictionless, and comfortable healthcare experience for patients in the outback and remote Australia.”

RFDS began work with Oracle in January 2022. With the creation of the national unified Aeromedical EHS powered on Oracle Autonomous Database, RFDS has eliminated paper-based record keeping and welcomed a single source of truth. Patient and emergency incident data can now be synchronised automatically in the field, back at base, across operation centres, and with other healthcare providers. A national fleet of application programming interfaces (APIs) powered by Oracle Integration Cloud are interconnected with Oracle Autonomous Database, enabling RFDS’ branches across the country to transact data securely across state borders and with national entities, such as the Australian Digital Health Agency and hospitals.

Additionally, RFDS uses Oracle GoldenGate to create a digital data twin for offline mode that allows live replication of the database. This enables field doctors in the outback of Australia to use a tablet to enter and retrieve the latest patient information without an internet connection. At the same time, RFDS is using Oracle Business Intelligence (BI) to create dashboards for monitoring the efficiency and effectiveness of its assets, as medical staff attend to patient emergencies or transfer care. RFDS’ electronic health record system runs on Microsoft Azure while Oracle Integration Cloud automates end-to-end processes and centralises management by enabling an API fleet, microservices, and application integrations.

“RFDS provides an incredible service to the Australian Outback and we are honoured to collaborate with them on their innovative and digital health modernisation journey,” said Stephen Bovis, regional managing director, Australia and New Zealand, Oracle. “The challenges of the pandemic have underscored the critical importance for healthcare organisations to have access to modern technologies and the capabilities they bring. Oracle’s leadership in cloud and database offerings is the result of decades of innovation and the breadth of our portfolio puts powerful tools in the hands of our customers.”

Offering a combination of proprietary image enhancing technology and the ability to switch between vascular and cardiac assessments with one device at the point of care, GE HealthCare has launched the handheld ultrasound device Vscan Air SL at the European Society of Cardiology (ESC) Congress in Amsterdam, the Netherlands.

Emphasizing the proprietary SignalMax and XDclear technologies available with Vscan Air SL, GE HealthCare said the handheld ultrasound device offers enhanced sensitivity and resolution.

The dual-headed probe of Vscan Air SL also enables clinicians to access sector and linear arrays on the same device, a capability that facilitates rapid vascular and cardiac assessments of patients, according to GE HealthCare.

“Having ever more powerful handheld ultrasound is a game changer for patient care. Whether on the ward or in general practice, being able to provide high-quality imaging at the point of care means rapid diagnosis and rapid treatment,” noted Guy Lloyd, M.D., FRCP, a consultant cardiologist at Barts Heart Center and University College London Hospitals.

GE HealthCare noted that Vscan Air SL, which has garnered FDA 510(k) clearance, will be commercially available in the United States within the next month. The device is currently available in Austria and New Zealand as well as countries in Asia and Europe, according to the company.